Issue 62, 2014

Albumin–graphene oxide conjugates; carriers for anticancer drugs

Abstract

In order to improve its biological properties, graphene oxide can be modified with hydrophilic polymers. Therefore, in this study, the surface of graphene oxide was modified with polyethylene glycol and albumin by covalent methods. In the subsequent step, paclitaxel which is a hydrophobic anticancer drug was loaded onto the surface of the functionalized graphene by π–π interactions. The synthesis of the nanocarrier and its interaction with paclitaxel were evaluated by FT-IR, CD, TEM, UV, AFM, DLS and fluorescence experiments. Release of the loaded drug from albumin–graphene conjugate was investigated at pH 5.4, 6.8 and 7.4.

Graphical abstract: Albumin–graphene oxide conjugates; carriers for anticancer drugs

Article information

Article type
Paper
Submitted
14 Jun 2014
Accepted
09 Jul 2014
First published
09 Jul 2014

RSC Adv., 2014,4, 33001-33006

Albumin–graphene oxide conjugates; carriers for anticancer drugs

S. Jokar, A. Pourjavadi and M. Adeli, RSC Adv., 2014, 4, 33001 DOI: 10.1039/C4RA05752J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements